Core Viewpoint - The company has actively implemented its "Quality Improvement and Efficiency Enhancement" action plan for 2025, focusing on R&D and innovation to enhance core competitiveness and investor returns [1][2][3]. Group 1: R&D and Innovation - The company is one of the earliest domestic enterprises specializing in RNA isothermal amplification technology, aiming to develop innovative diagnostic technologies and products to meet unmet clinical needs [1]. - The company has successfully developed a new technology platform "Digital SAT + Fully Automatic Supporting Equipment DigiNAT," which shows significant advantages over digital PCR technology, including simplified sample processing and faster detection speed [2][3]. - The company has initiated the development of RNA digital quantitative detection products, focusing on tumor screening and diagnosis, with progress in products for prostate cancer and bladder cancer [3]. Group 2: Market Development and Marketing Capability - The company has expanded its marketing network, developing 91 new terminal customers and adding 206 new products to hospitals, resulting in over 50% year-on-year revenue growth for certain blood-related products [4][5]. - The company has strengthened its academic promotion system, enhancing brand recognition and professional influence in core product lines [5]. Group 3: Internal Control and Cost Management - The company emphasizes cost control and efficiency enhancement, optimizing procurement management and improving resource utilization to lower operational costs [6]. - The company is actively monitoring industry policies and regulations to enhance internal control systems and ensure effective execution [6]. Group 4: Corporate Governance - The company is committed to improving its corporate governance structure and compliance awareness among key stakeholders, including major shareholders and executives [6][7]. - The company organizes training for its board members to enhance their understanding of securities market regulations and compliance [7]. Group 5: Investor Relations and Shareholder Returns - The company prioritizes investor relations management, ensuring accurate and timely information disclosure to maintain a positive market image [7]. - The company has established a reasonable profit distribution plan to reward investors, having completed the distribution of cash dividends for 2024 [7].